TRABECTEDIN | N220837 | APOTEX INC
1 strength1 unique patent0 unique exclusivities
Products (1)
Patents (1)
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|
| 12303506 | Feb 18, 2043 | — | — | Yes | — | — |
ADDED7/1/2026
Apotex received FDA approval (NDA 220837) for Evdi (trabectedin), expanding generic competition in the trabectedin market.
ADDED7/1/2026
Apotex added U.S. Patent 12,303,506 to the Orange Book listing for Evdi (trabectedin), NDA 220837.